Foundayo GLP-1 Pill: FDA Needs More Data

Foundayo GLP-1 Pill: FDA Needs More Data

Orforglipron (also known as Foundayo) is one of the most promising drugs in the GLP-1 space, notably as only the second oral GLP-1 option for obesity. Unlike injectable treatments, it does not require refrigeration and is easier to scale for widespread use.

Dave highlights the ongoing questions that linger about the drugs approval as it relates to liver safety.

Det här avsnittet är hämtat från ett öppet RSS-flöde och publiceras inte av Podme. Det kan innehålla reklam.

Avsnitt(197)

How To Get $50 GLP-1

How To Get $50 GLP-1

Millions of Medicare beneficiaries are about to gain access to GLP-1 weight loss medications for as little as $50 per month through the new Medicare Bridge Program, launching July 1. In this episode o...

23 Juni 44min

What Comes After Zepbound? The Biggest ADA 2026 Obesity Drug Breakthroughs

What Comes After Zepbound? The Biggest ADA 2026 Obesity Drug Breakthroughs

ADA 2026 delivered a massive wave of obesity and diabetes data, and in this episode of On The Pen, Dave Knapp (@manonthemounjaro) sits down with Jen (@JcanNuSH) ​⁠ to break down the molecules, clinica...

16 Juni 1h 15min

Retatrutide Just Reached Bariatric Surgery Results

Retatrutide Just Reached Bariatric Surgery Results

Dave sits down with nurse practitioner and former Retatrutide clinical trial participant David White to break down the biggest obesity headlines from the 2026 American Diabetes Association Conference....

11 Juni 48min

Retatrutide Before FDA Approval? Lilly Just Changed the Conversation

Retatrutide Before FDA Approval? Lilly Just Changed the Conversation

Dave breaks down an unreported Expanded Access Pathway that Eli Lilly has quietly established for Retatrutide.

9 Juni 20min

Eli Lilly Isn’t Telling Us About Their Future Obesity Drugs

Eli Lilly Isn’t Telling Us About Their Future Obesity Drugs

Does Eli Lilly already have the solve for obesity? In this episode of On the Pen — the Weekly Dose Podcast, host Dave Knapp breaks down a stunning comment from Lilly's Chief Scientific Officer Daniel ...

2 Juni 20min

Retatrutide, Multi Agonist Obesity Drugs, and the PBM Access War

Retatrutide, Multi Agonist Obesity Drugs, and the PBM Access War

https://linktr.ee/manonthemounjaro

26 Maj 30min

Lilly Bets $8B on Weight Loss Future

Lilly Bets $8B on Weight Loss Future

https://linktr.ee/manonthemounjaro

19 Maj 23min

The Next Two Weeks in GLP1 Are Huge, Here's Why

The Next Two Weeks in GLP1 Are Huge, Here's Why

http://www.otplinks.com

12 Maj 1h 7min

Populärt inom Hälsa

somna-med-henrik
rss-bara-en-till-om-missbruk-medberoende-2
inga-beiga-morsor
rss-vuxna-pa-latsas
sexnoveller-deluxe
not-fanny-anymore
angestpodden
rss-viktmedicinpodden
johannes-hansen-podcast
sova-med-dan-horning
brottarbroder
medicinvetarna
rss-hos-psykologen
sa-in-i-sjalen
sex-pa-riktigt-med-marika-smith
rss-traningsklubben
rss-basta-livet
rss-stark-sarbar
psykologsnack
rss-pappahjartat